Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of CM310 Recombinant Humanized Monoclonal Antibody Injection in Patients With Seasonal Allergic Rhinitis Under Background Treatment

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Apr 2025 According to the KeyMed Biosciences Media Release, the results from this study were published in Nature Medicine.
05 Apr 2025 Results presented in the KeyMed Biosciences Media Release.
07 Feb 2025 According to the KeyMed Biosciences Media Release, company announced the National Medical Products Administration (NMPA) of China has recently approved the supplemental New Drug Application (sNDA) of Stapokibart, for the treatment of seasonal allergic rhinitis, this approval is based on results from this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com